Navigation Links
Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
Date:9/28/2007

ns are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and the Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, each as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838


'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Front-face detection for high-concentrate, opaque or solid sample
4. Concentrated solar energy project wins Innovation Days prizes
5. Wisconsin stands at the center of scientific efforts to avert flu epidemics
6. Thompsons HHS legacy will include efforts to combat disease in Africa
7. Efforts to avoid friendly fire spawned ancestor of todays RFID
8. Manufacturing group says efforts led to big improvements
9. Madison grid computing efforts attack big research questions
10. Californian stem-cell efforts get new rules, attract lawsuits
11. Tech Council passes E-Learning efforts for Northern Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , SAN DIEGO, Sept. 8 eBioscience Corporation, ... today the acquisition of NatuTec GmbH, a leading distributor of high-quality ... , , "For the past 10 years, NatuTec ... Todd R. Nelson, CEO of eBioscience. "The NatuTec acquisition provides ...
... , LAIYANG, China, Sept. 8 ... "Company", "Jiangbo"), a,U.S. pharmaceutical company with its principal operations ... announced guidance for,fiscal year 2009. The Company expects ... million in revenue and operating income of $40 to ...
... , , RICHMOND, Calif., ... Institute used zinc finger nucleases (ZFNs) designed by Sangamo BioSciences, ... modify the genomes of human embryonic stem cells (hESCs) and ... useful tools in drug discovery and development. Scientists also ...
Cached Biology Technology:eBioscience Corporation Acquires NatuTec GmbH 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 2Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 3Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 4
(Date:4/23/2014)... Huntington,s disease, most in their mid-thirties and forties, ... behavioral decline within two decades. "Mutant" protein clusters, ... disease, have been the primary focus of therapies ... new research from Prof. Gerardo Lederkremer and Dr. ... Cell Research and Immunology, in collaboration with Prof. ...
(Date:4/23/2014)... Valley, NY. (Apr. 23 2014) A ... neural stem cells (hNSCs) into the brains of ... after 22 and 24 months found that the ... and did not cause tumors. , The study ... Cell Transplantation but is currently freely ...
(Date:4/23/2014)... trope that the likelihood of an accurate group decision ... hold up when a collective faces a variety of ... Instead, Princeton University researchers report that smaller groups actually ... may become excessively focused on only certain pieces of ... what is known about collective intelligence, or the "wisdom ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... COLD SPRING HARBOR, N.Y. Combining ... with the versatility of lentiviral vectors gives researchers ... function both in vivo and in vitro. ... Protocols ( www.cshprotocols.org/TOCs/toc8_08.dtl ) features a pair ...
... parasite has waged a successful guerrilla war against the human ... Journal of Biological Chemistry has exposed one of ... which may aid in future drug development. , Malaria parasites ... their human hosts the parasites first set up shop in ...
... Cambridge, UK, 04 August 2008 - Disease Models & ... focus on translational research and the use of model organisms ... Biologists, DMM is a highly anticipated biomedical research ... and online today at http://DMM.biologists.org . DMM ...
Cached Biology News:Research exposes new target for malaria drugs 2Building bridges between the clinic and the laboratory 2
... The INK4a-ARF locus encodes two unrelated proteins ... p14^ARF^ arrests the cell cycle in a ... promotes the rapid degradation of mdm2 proteinrequired ... and accumulation. This interaction is mediated ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Mfr ...
... Insulin exerts its ... the insulin receptor, a ... of two Alpha subunits ... arranged in the following ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z37,208-0) ... assistance. Mfr Desig: Corning ...
Biology Products: